Free Trial

Elekta AB (publ) (OTCMKTS:EKTAY) Releases Earnings Results, Misses Estimates By $0.01 EPS

Elekta AB (publ) logo with Medical background

Elekta AB (publ) (OTCMKTS:EKTAY - Get Free Report) posted its quarterly earnings results on Friday. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01), Zacks reports. Elekta AB (publ) had a net margin of 5.65% and a return on equity of 11.07%. The business had revenue of $416.86 million during the quarter, compared to analysts' expectations of $435.89 million.

Elekta AB (publ) Trading Down 8.0 %

Shares of OTCMKTS:EKTAY traded down $0.49 during mid-day trading on Friday, reaching $5.60. 5,517 shares of the company were exchanged, compared to its average volume of 4,536. Elekta AB has a 1 year low of $5.25 and a 1 year high of $8.24. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.05 and a quick ratio of 0.81. The firm's 50-day simple moving average is $5.71 and its 200 day simple moving average is $6.09. The firm has a market cap of $2.15 billion, a price-to-earnings ratio of 22.40 and a beta of 1.22.

Elekta AB (publ) Cuts Dividend

The company also recently declared a dividend, which will be paid on Thursday, March 27th. Stockholders of record on Friday, March 7th will be issued a dividend of $0.1072 per share. The ex-dividend date of this dividend is Friday, March 7th. Elekta AB (publ)'s dividend payout ratio is currently 48.00%.

Wall Street Analysts Forecast Growth

Separately, Sanford C. Bernstein raised shares of Elekta AB (publ) from a "strong sell" rating to a "hold" rating in a research note on Wednesday, January 29th.

Read Our Latest Stock Analysis on Elekta AB (publ)

About Elekta AB (publ)

(Get Free Report)

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.

Recommended Stories

Earnings History for Elekta AB (publ) (OTCMKTS:EKTAY)

Should You Invest $1,000 in Elekta AB (publ) Right Now?

Before you consider Elekta AB (publ), you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elekta AB (publ) wasn't on the list.

While Elekta AB (publ) currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings: Will it Spark a Rally or Trigger a Sell-Off?
Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
The EXACT Date of Next Stock Market Crash

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines